{"id":"W3026903046","doi":"10.1158/1078-0432.ccr-19-4121","title":"EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression","year":2020,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":132,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ontario Genomics; Ozmosis Research (Canada); Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto","funders":"Ontario Institute for Cancer Research; Princess Margaret Cancer Foundation","keywords":"Olaparib; Ovarian cancer; Medicine; PARP inhibitor; Oncology; Clinical trial; Internal medicine; Phases of clinical research; Open label; Cancer; Cancer research; Poly ADP ribose polymerase; Biology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001978026,0.00123446,0.001452796,0.0003547183,0.0004498917,0.001046997,0.000800725,0.00105872,0.004517343],"category_scores_gemma":[0.001094432,0.0004496192,0.0008086328,0.0003370156,0.001142648,0.0009905481,0.0004943798,0.00268585,0.0006959593],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009210935,"about_ca_system_score_gemma":0.001445625,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006857717,"about_ca_topic_score_gemma":0.00218175,"domain_scores_codex":[0.999567,0.0002300781,0.0000213337,0.00007118405,0.00003927627,0.00007111539],"domain_scores_gemma":[0.9992571,0.0001161086,0.0001527299,0.00007056943,0.00004579174,0.0003577509],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8613972,0.05257536,0.004897381,0.0005376054,0.000758897,0.0001658674,0.0002799256,0.001621105,0.02202027,0.0003950562,0.003540153,0.05181116],"study_design_scores_gemma":[0.7491607,0.2384702,0.006506316,0.00002465682,0.0002098501,0.0001683772,0.00005910707,0.00110755,0.002121204,0.0002543014,0.001896262,0.00002146594],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9938943,0.0009741282,0.0003085817,0.0003337681,0.00007996809,0.002086425,0.0008387338,0.00006343306,0.001420635],"genre_scores_gemma":[0.9903408,0.0007872844,0.001398431,0.0007410213,0.0001681958,0.002312083,0.002040743,0.00002236713,0.002189154],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004517343,"threshold_uncertainty_score":0.01511204,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.5458711143040862,"score_gpt":0.62167981321802,"score_spread":0.07580869891393383,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}